Dainippon Of Japan Seeks Approval For First-Line Diabetes Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma has applied for approval of a reformulated version of metformin, a diabetes drug. Dainippon wants to sell its SMP-862 drug in a larger dose as the primary treatment for Type 2 diabetes. Metformin itself was approved in Japan in 1961 as Melbin, but has been approved only as a second-line treatment in case other drugs fail to work. The company is relying on foreign trials rather than conducting new trials, because it licensed the drug from Merck Sante. (Click here for more - a subscription may be required